Henlius in Advanced Talks with J&J and Roche for $100M+ Upfront Deal on PD-L1 ADC HLX43

Sep 16, 2025 16:38 CST Updated 16:38

Henlius

Innovative Biopharmaceutical Company

Johnson & Johnson

Medical Device R&D and Manufacturer

The Opportunity for Financing Has Arrived!~
Multiple well-known VC firms seek high-quality investment targets,
Pipelines of interest include:
(1) Innovative TCE for solid tumors, (2) Innovative radiopharmaceuticals with new targets/new radionuclides, (3) CNS innovative drugs such as Abeta dual-target, (4) Self-immune innovative drugs with new targets/new MOA.
Biotech companies with relevant products are requested to contact the PharmTimes BD team immediately (BD@drugtimes.cn）！
Main Text: 1000Character
Estimated reading time:3Minute

September 16, 2025Bloomberg NewsCiting informed sources,Shanghai Henlius Biotech, Inc. andJohnson & Johnson and Roche on ADC DrugsHLX43Negotiate authorized transactions.

It is reported that,After the deal is reached, Shanghai Henlius Biotech, Inc. will obtainHundreds of millions of dollars in upfront payments,If specific regional rights are retained and R&D milestones are achieved, phased payments and royalties will also be received.

HLX43 is an ADC targeting PD-L1, with a payload of topoisomerase inhibitor and a DAR of approximately 8. As a drug possessing dual mechanisms of precise toxin killing and tumor immunotherapy,The drug inThis Year'sShowcased its excellent broad-spectrum capabilities at the WCLC conference.

Specifically, inHLX43ClinicalIIn the phase study (56 NSCLC patients enrolled)Patient),For evaluable patients (n=54),The overall ORR was 37.0%.DCR is 87.0%。

It is worth mentioning that,InAmong 26 non-squamous cancer patients who received three or more lines of treatment,ORR still reached 46.2%, with DCR as high as 96.2%; andAmong 28 squamous cell carcinoma patients who had received four or more lines of treatment,ORR reached 28.6%, and 82.1% of patients achieved effective disease control.

Further subgroup analysis showed that inEGFR Wild-Type Non-Squamous NSCLC Patients (n=15)In China,The confirmed objective response rate (cORR) was as high as 46.7%, and the disease control rate (DCR) reached 93.3%.Moreover, the expression level of PD-L1 did not affect the efficacy, with ORR and DCR being similar between TPS ≥1% and <1%.

In summary, in this Phase I study, HLX43 demonstrated stronger benefit potential in subgroups such as immunotherapy-resistant populations and EGFR wild-type lung adenocarcinoma populations.

Based on its dual mechanism, HLX43 may also achieve breakthroughs as a single agent in immunotherapy-resistant populations. It could also be combined with chemotherapy, radiotherapy, or even targeted drugs or anti-angiogenic drugs in specific populations, with the potential for further synergistic enhancement.

In August this year, Shanghai Henlius Biotech, Inc. announced that the international multicenter Phase II clinical study (HLX43-NSCLC201) of its HLX43 in NSCLC patients had completed the first dosing of a subject in the United States. Subsequently, the study will be gradually launched in China, the U.S., Japan, and Australia.

According to foreign media business news analysis, whether the deal can be reached is still unknown.Clinical risks are the primary concern.Mid-term data may not guarantee the success of later trials; its safety and efficacy must meet the high standards of European and American regulatory agencies, while clinical trial data in China is facing stricter scrutiny.

Secondly,Negotiation strategies may also become variables.There are reports that Shanghai Henlius Biotech, Inc. may seek a higher valuation as the trials progress, which could delay the transaction process. Competitive pressure is also not to be ignored, with other pharmaceutical companiesIf similar drugs being developed are approved first, the commercial potential of HLX43 may be diluted.

Finally,Geopolitical risks also need to be vigilant.The impact of U.S.-China relations on cross-border biotech cooperation continues, with stricter regulatory scrutiny potentially affecting deal structures and timelines.Recommended Reading:Trump Takes a Swipe at China BD Deals, Netizens Are Divided ——

References:

1.Bloomberg

2. WCLC Expert Says | Professor Wang Jie: HLX43 Demonstrates Broad-Spectrum Antitumor Potential, PD-L1 ADC Opens a New Chapter in Solid Tumor Treatment (Shanghai Henlius Biotech, Inc.)

3.https://business-news-today.com/why-henlius-biotechs-hlx43-deal-talks-with-johnson-johnson-and-roche-are-shaking-up-global-oncology/

4. Other Public Information

NextYesA ConferencePromotion：

Currently, PharmaTimes and the Hepatitis New Drug Alliance have decided, in response to industry demand, toNovember 21-22, 2025Held in Shanghai"4th Annual Meeting of the Liver Disease New Drug Alliance and Weight Loss New Drug Forum"Event (Offline). The event is honored to invite multiple senior experts in the industry, focusing on the latest research achievements, clinical practices, and future development directions in the field of liver diseases and related areas. Experts and scholars from hospitals, pharmaceutical companies, CROs, investment institutions, and other organizations will gather to share their industry insights and valuable experiences from different perspectives. Readers who are interested are welcome to stay tuned. The PharmaTimes official account will continue to update the latest developments of the conference.

Hosted by:Hepatitis New Drug Alliance, PharmaTimes

Co-organizer:Chronic Disease Management Branch of China Medical Biotechnology Association, Fatty Liver Expert Committee of Chinese Medical Doctor Association, Love Liver Alliance.

Booths are booking up fast! Contact information is as follows:

Sponsorship formats include but are not limited to speaking slots, exhibition booths, color pages in the conference brochure, dinner sponsorship, and promotional materials for the conference.

Image Source: Jimo AI

Copyright Statement/Disclaimer
This article is an original piece.
This article is for information exchange purposes only and does not provide any commercial, medical, or investment advice.
The images, videos, fonts, music, and other materials in the article are either authorized genuine works purchased by PharmaTimes, sourced from the WeChat public image library, taken from the company's official website or the Internet, or used in accordance with the CC0 protocol. All copyrights belong to their respective owners, and PharmaTimes makes every effort to credit the sources.
If you have any questions, please contact us.
Sincerely grateful!
DrugTimes Official Website: www.drugtimes.cn
Contact Information:
Phone: 13651980212
WeChat: 27674131
Email: contact@drugtimes.cn
ClickView the exciting activities of the previous Hepatitis New Drug Alliance!